Clement Lewin is a Principal at CSL Vaccine Consulting with expertise in medical affairs, policy, and strategy. Until the end of 2020, he headed the BARDA Office and NV Stakeholder Engagement for Sanofi Pasteur where he played an instrumental role in securing and managing over $2 billion in BARDA funding for pandemic influenza and COVID-19 vaccines development as well as serving as one of the external spokespeople for the COVID-19 program.

Clem has 25 years of experience in vaccines in roles of increasing responsibility. He started at Merck and held several domestic and international positions. At Chiron Vaccines, he served as Vice President Strategic Planning & Business Intelligence and then Vice President Government Affairs & Immunization Policy for the US. He then joined Acambis overseeing Government Affairs, the Strategic Planning process, and Marketing playing a key role in licensing ACAM2000, a cell culture-based smallpox vaccine, and securing a ten-year $450 million contract with the United States Government to supply the vaccine. Clem headed Medical Affairs & Immunization Policy for North America where he was responsible for Medical Affairs activities; the CDC and National Vaccine Program Office helping launch several vaccines and manage the response to the 2009 pandemic. In addition to his experience in vaccines, Clem was at Bayer Pharmaceuticals as Director of Global Scientific Affairs for their anti-infective franchise.

Clem obtained his BSc and Ph.D. from the University of London. After five years as a Research Fellow at the Universities of London and Edinburgh. He published over 50 papers in peer-reviewed journals on mechanisms of action and resistance to antibacterials leaving research to obtain an MBA with distinction from Cornell University and joining the life sciences practice of Pittiglio Rabin Todd & McGrath, specializing in product development issues.

Clem was the Biotechnology Innovation Organization liaison to the Advisory Committee on Immunization Practices from 2004 to 2014. He served on the National Vaccine Advisory Committee from 2009-2012. He was on the advisory board of Bio Ventures for Global Health and a board member of the Alliance for Biosecurity. He currently serves on the Board of Trustees of Gaylord Hospital, a long-term acute care facility in Connecticut.